CytomX Therapeutics will get a $50m upfront payment from Bristol-Myers Squibb and is eligible to receive up to $1.2bn in milestone fees plus research funding and royalties under an agreement to discover, develop and commercialize novel immunotherapies.
Bristol-Myers commits up to $1.2bn in CytomX deal
CytomX Therapeutics will get a $50m upfront payment from Bristol-Myers Squibb and is eligible to receive up to $1.2bn in milestone fees plus research funding and royalties under an agreement to discover, develop and commercialize novel immunotherapies.
More from Anticancer
More from Therapy Areas
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.
• By
CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.